Forsnevring i aortaklaffen, aortastenose

Dette dokumentet er basert på det profesjonelle dokumentet Aortastenose. Referanselisten for dette dokumentet vises nedenfor.

1. Grimard BH, Safford RE, Burns EL. Aortic stenosis: diagnosis and treatment. Am Fam Physician. 2016 Mar 1;93(5):371-378.
2. Joseph J, Naqvi SY, Giri J, Goldberg S. Aortic Stenosis: Pathophysiology, Diagnosis, and Therapy. Am J Med. 2017;130(3):253-263. PMID: 27810479. PubMed 
3. Nkomo VT, Gardin JM, Skelton TM, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005-11. PubMed 
4. Eveborn GW, Schirmer H, Heggelund G, et al. The evolving epidemiology of valvular aortic stenosis. the Tromsø study. Heart 2013; 99:396. PubMed 
5. Yadgir S, Johnson CO, Aboyans V, et al. Global Burden of Disease Study Nonrheumatic Valve Disease Collaborators. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017 . Circulation 2020; 141: 1670-80. pmid:32223336 PubMed 
6. Lewin MB, Otto CM. The bicuspid aortic valve: adverse outcomes from infancy to old age. Circulation. 2005;111(7):832–834.
7. Kaiser Y, Nurmohamed NS, Kroon J. Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. Heart 2022. doi:10.1136/heartjnl-2021-319804 DOI 
8. Chan K-L. Lipoprotein(a) and aortic stenosis. Editorial. Heart 2021. doi:10.1136/heartjnl-2021-320173 DOI 
9. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022. doi:10.1093/eurheartj/ehac361 DOI 
10. Gaasch WH. Natural history, epidemiology, and prognosis of aortic stenosis. UpToDate, last updated Apr 13, 2020. UpToDate 
11. Otto CM. Clinical features and evaluation of aortic stenosis in adults. UpToDate 2013.
12. Kassis N, Hariri EH, Karrthik AK, et al. Supplemental calcium and vitamin D and long-term mortality in aortic stenosis. Heart 2022; 108: 964-72. pmid:35470234 PubMed 
13. Lau FD, Giugliano RP. Lipoprotein(a) and its Significance in Cardiovascular Disease A Review. JAMA Cardiol 2022. doi:10.1001/jamacardio.2022.0987 DOI 
14. Frey N, Steeds RP, Rudolph TK, et al. Symptoms, disease severity and treatment of adults with a new diagnosis of severe aortic stenosis. Heart 2019; 105: 1709-16. pmid:31302639 PubMed 
15. Chambers J. Aortic stenosis. BMJ 2005; 330: 801-2. PubMed 
16. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021. doi:10.1093/eurheartj/ehab395 DOI 
17. Thomassen HK, Cioffi G, Gerdts E, et al. Echocardiographic aortic valve calcification and outcomes in women and men with aortic stenosis . Heart 2017. doi:10.1136/heartjnl-2016-311040 DOI 
18. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(22):2438–2488.
19. Nguyen V, Estellat C, Codogno I, et al . Haemodynamic and anatomic progression of aortic stenosis. Heart 2015. doi:10.1136/heartjnl-2014-307154 DOI 
20. Anand A, Chin C, Shah ASV, et al. Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis . Heart 2017. doi:10.1136/heartjnl-2017-312257 DOI 
21. Monin JL, Lancellotti P, Monchi M, et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation 2009; 120: 69-75. Circulation 
22. Ben-Dor I, Pichard AD, Gonzalez MA, et al. Correlates and causes of death in patients with severe symptomatic aortic stenosis who are not eligible to participate in a clinical trial of transcatheter aortic valve implantation. Circulation. 2010;122(11 suppl):S37–S42.
23. Makkar RR, Fontana GP, Jilaihawi H, et al.; PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366(18):1696–1704.
24. Wang TY, Svensson LG, Wen J, et al. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve. NEJM Evidence 2023. doi:10.1056/EVIDoa2300067 DOI 
25. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on pregression of aortic stenosis. Results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; : PMID: 20048204. PubMed 
26. El-Hamamsy I, Eryigit Z, Stevens L-M, et al. Long term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomisedm controlled trial. Lancet 2010; 376: 524-31. PubMed 
27. Nasjonalt kunnskapssenter for helsetjenesten. Kateterbasert implantasjon av aortaklaffer. Oslo, 03.09.2008
28. Steigen TK, Schive B, Næsheim T, Busund R. Transkateter aortaventilimplantasjon ved aortastenose. Tidsskr Nor Legeforen 2011; 131: 343-8. Tidsskrift for Den norske legeforening 
29. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-95. New England Journal of Medicine 
30. Woldendorp K, Indja B, Bannon PG, et al. Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur Heart J 2021. pmid:33517376 PubMed 
31. Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA 2013; 310: 2069-77. doi:10.1001/jama.2013.282043 DOI 
32. Leon MB, Smith CR, Mack MJ, et al. for the PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016. doi: 10.1056/NEJMoa1514616 DOI 
33. Van Mieghem NM, Deeb GM, Søndergaard L, et al. Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial. JAMA Cardiol 2022; 7: 1000-1008. pmid:36001335 PubMed 
34. Zahn R, Werner N, Gerckens U, et al. Five-year follow-up after transcatheter aortic valve implantation for symptomatic aortic stenosis . Heart 2017. doi:10.1136/heartjnl-2016-311004 DOI 
35. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid-lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-56. New England Journal of Medicine 
36. Varadarajan P, Kapoor N, Bansal RC, et al. Clinical profile and natural history of 453 nonsurgically managed patients wiith severe aortic stenosis. Ann Thorac Surg 2006; 82: 2111-5. PubMed 
37. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J 1988; 9(suppl E): 57-64.
38. Sharabiani MTA, Fiorentino F, Angelini GD, Patel NN. Long-term survival after surgical aortic valve replacement among patients over 65 years of age. Open Heart 2016. doi:10.1136/openhrt-2015-000338 DOI 
39. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA 2008; 300: 1317-25. Journal of the American Medical Association